Alzheon To Present At Upcoming Industry Conferences

Company Executives Selected for Scientific and Business Presentations, Including Keynote Address, about Alzheimer’s Disease and CNS Drug Development

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will be making presentations about drug development in Alzheimer’s and central nervous system (CNS) diseases at several upcoming industry conferences.

Event:
CNS Diseases World Summit

• Title: R&D Panel: What Sells Big Pharma in CNS
• Presenter: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
• Date: Wednesday, September 14, at 8:30 a.m.
• Location: Hyatt Regency Boston Harbor, Boston, Mass.
  
  

• Title: CNS: Present and Future
• Presenter: Susan Abushakra, MD, Chief Medical Officer of Alzheon
• Date: Wednesday, September 14, at 2:15 p.m.
• Location: Hyatt Regency Boston Harbor, Boston, Mass.

Event:
The Pharmaceutical Strategy Conference

• Title: R&D Panel: Breaking Through in Alzheimer’s
• Presenter: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
• Date: Thursday, September 29, at 9:30 a.m.
• Location: Marriott Marquis Times Square, New York, N.Y.

Event:
Partnerships in Clinical Trials Conference

• Title: Keynote: Innovation in Clinical R&D: Finding a Cure for Alzheimer’s
• Presenter: Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon
• Date: Thursday, October 6, at 8:15 a.m.
• Location: Boston Convention and Exhibition Center, Boston, Mass.

Event:
Strategic Partnerships in Drug Repurposing Forum

• Title: The Impact of Using Data to Reposition a Drug
• Presenter: John Hey, PhD, Chief Scientific Officer of Alzheon
• Date: Friday, October 28, at 3:30 p.m.
• Location: Wyndham Boston Beacon Hill, Boston, Mass.

About Alzheon
Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been tested in clinical trials involving over 2,000 Alzheimer’s patients. We utilize a precision medicine approach based on genetic and patient information to design therapies with the greatest impact. Our mission is to apply our clinical expertise and technology platform to develop novel therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders. For more information, please visit www.alzheon.com.